Affimed NV said a combination of its AFM13 drug and Merck & Co. Inc.'s Keytruda was well-tolerated in patients with relapsed or refractory Hodgkin lymphoma in an ongoing phase 1b study.
The combination treatment is being investigated as a salvage therapy for patients who have failed prior standard treatments like brentuximab vedotin.
The early results showed a three-month overall response rate of 83%, compared to the historical overall response rate of Keytruda as a monotherapy of 58% to 63%.
Affimed said the most common side effects observed were infusion-related reactions, nausea, diarrhea, headache, pyrexia and rash.
The preliminary data was presented by Affimed at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta.